Pharma Focus Asia

Samsung Biologics Plans to Construct New Manufacturing Facility


Samsung Biologics plans to expand its presence with the construction of a new manufacturing facility located at Incheon.


The new facility is designed for drug product capacity to meet the growing demand of drugs and also to ensure flexible production capabilities.

The expansion includes addition of small-scale cartridge and syringe filling to Drug Product (DP) offerings and by raising the total lyophilisation capacity by 246 per cent of the existing capacity.

The project investments include building of a flexible filling line and two additional lyophiliser units with 41.2 m2 chambers.

The new project with a flexible filling line is expected to start GMP operations in the second half of 2021. In addition, expanded lyophilisation line will become operational in the first half of 2022.


NameSamsung Biologics
TypeNew Construction
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?